Search / Trial NCT06615921

A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection

Launched by TAKEDA · Sep 26, 2024

Trial Information

Current as of December 30, 2024

Recruiting

Keywords

Drug Therapy

ClinConnect Summary

This clinical trial is studying a medication called Maribavir to see how well it works in treating adults who have a virus called Cytomegalovirus (CMV) after receiving a transplant. The main goal is to find out how effectively Maribavir can help clear CMV from the blood of these patients. Researchers also want to understand how Maribavir is used in everyday medical practice and gather information about the types of patients receiving this treatment, along with the healthcare resources used for managing CMV.

To participate in this trial, individuals must be at least 18 years old, have received a stem cell or organ transplant, and have been diagnosed with a CMV infection after their transplant. They should have started treatment with Maribavir at least four months before joining the study. Participants will not need to undergo any new tests; instead, the study will review existing medical records to gather information. Those interested in this trial should know that their participation can help improve understanding and treatment of CMV infections in the future.

Gender

ALL

Eligibility criteria

  • Inclusion criteria:
  • Aged greater than or equal to (\>=) 18 years at the time of consent or start of chart abstraction in case a consent waiver will be allowed as per local regulation.
  • Received an HSCT/SOT.
  • Diagnosed with CMV infection/disease any time after the HSCT/SOT date.
  • Initiated maribavir at least 4 months before the chart abstraction date (or at time of Central Ethics Committee \[CEC\]/Local Ethics Committee \[LEC\] submission as per local regulation).
  • Participants with hospital medical chart available, who signed an informed consent form before starting any study procedures (unless waiver is allowed as per local regulation).
  • Exclusion criteria:
  • Participants who do not provide informed consent, where consent is required per country regulations.
  • Participants who participated to Clinical Trials investigating maribavir.

Trial Officials

Study Director

Study Director

Takeda

About Takeda

Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.

Locations

Granada, , Spain

Madrid, , Spain

Ulm, , Germany

Santander, Cantabria, Spain

Montpellier, , France

Manchester, , United Kingdom

Bilbao, , Spain

Barcelona, , Spain

London, , United Kingdom

Geneva, , Switzerland

Greifswald, , Germany

Madrid, , Spain

Novi Sad, , Serbia

Strasbourg, , France

Paris, , France

Aachen, , Germany

Birmingham, , United Kingdom

Rotterdam, , Netherlands

Leipzig, , Germany

London, , United Kingdom

Southampton, , United Kingdom

Wurzburg, , Germany

Vienna, , Austria

Copenaghen, , Denmark

Bordeaux, , France

Dijon, , France

Lille, , France

Nice, , France

Paris, , France

Paris, , France

Toulouse, , France

Berlin, , Germany

Essen, , Germany

Hamburg, , Germany

Hannover, , Germany

Mainz, , Germany

Munich, , Germany

Roma, , Italy

Utrecht, , Netherlands

Belgrade, , Serbia

Las Palmas, , Spain

Cambridge, , United Kingdom

London, , United Kingdom

Newcastle, , United Kingdom

Nottingham, , United Kingdom

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0